DLL3-guided therapies in small-cell lung cancer: from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy

Abstract DLL3 acts as an inhibitory ligand that downregulates Notch signaling and is upregulated by ASCL1, a transcription factor prevalent in the small-cell lung cancer (SCLC) subtype SCLC-A. Currently, the therapeutic strategies targeting DLL3 are varied, including antibody-drug conjugates (ADCs),...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:Molecular Cancer
المؤلفون الرئيسيون: Po-Lan Su, Karthik Chakravarthy, Naoki Furuya, Jeremy Brownstein, Jianhua Yu, Meixiao Long, David Carbone, Zihai Li, Kai He
التنسيق: مقال
اللغة:الإنجليزية
منشور في: BMC 2024-05-01
الموضوعات:
DLL3
Small-cell lung cancer
Antibody-drug conjugate
T-cell engager
Radioimmunotherapy
الوصول للمادة أونلاين:https://doi.org/10.1186/s12943-024-02012-z

الانترنت

https://doi.org/10.1186/s12943-024-02012-z

مواد مشابهة